Insulin glulisine: adverse event reports filed with FDA

607

reports as suspect product

0% of all reports · about 30 a year

37

reports, 12 months to June 2026

12 in the 12 months before

94.2%

marked serious by the reporter

42.7% across the class

9.4%

record death among outcomes, as reported

57 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Insulin glulisine reports recording the termmedian drug in insulin analog

1. Blood glucose increasedraised blood sugar reading14.2%86
2. Hypoglycaemialow blood sugar13%79
3. Glycosylated haemoglobin increaseda raised HbA1c, the long-term sugar measure9.2%56
4. Hyperglycaemiahigh blood sugar8.6%52
5. Dizzinesslight-headedness or unsteadiness5.4%33
6. Blood glucose decreasedlow blood sugar reading5.3%32
7. Product dose omissiona dose was missed5.3%32
8. Diabetes mellitus inadequate controldiabetes not well controlled4.8%29
9. Dyspnoeashortness of breath4.4%27
10. Malaisegeneral feeling of being unwell4.1%25
11. Chest painchest pain4%24
12. Fatiguetiredness4%24
13. Pain in extremitypain in an arm or leg4%24
14. Falla fall3.8%23
15. Syncopefainting3.6%22
16. Blood glucose fluctuation3.5%21
17. Diabetic ketoacidosisa serious complication of diabetes with acid build-up3.3%20
18. Drug ineffectivethe medicine did not work as expected3.1%19
19. Painpain, site not specified3.1%19
20. Pneumonialung infection3%18
21. Hospitalisationadmission to hospital2.8%17
22. Inappropriate schedule of product administrationthe product was taken at the wrong times2.8%17
23. Cerebrovascular accidentstroke2.6%16
24. Coughcough2.6%16
25. Headachehead pain2.6%16
26. Influenzaflu2.6%16
27. Loss of consciousnesspassing out2.6%16
28. Visual impairmentreduced vision2.6%16
29. Vomitingbeing sick2.6%16
30. Blood glucose abnormal2.5%15

Top 30 of 282 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 26 drugs in the insulin analog class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 289,293 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 24.9% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 607 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the insulin analog class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Insulin glulisine as a suspect or interacting product; reports listing it only as a concomitant medication (674) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.